Bumi appoints Rothschild Group to evaluate Bakrie proposals

Indonesia-focused mining company Bumi said on Wednesday that it has appointed Rothschild Group to evaluate the proposed transactions by the Bakrie Group last week on the basis of their value for shareholders and whether they can be delivered.

Indonesia-focused mining company Bumi said on Wednesday that it has appointed Rothschild Group to evaluate the proposed transactions by the Bakrie Group last week on the basis of their value for shareholders and whether they can be delivered.

On Thursday 11th October, shares in Bumi leapt after the Bakrie Group, a major shareholder in the company, tabled an offer under which it would swap its stake in the group for a stake of equivalent value in Bumi Resources.

It was hoped that the proposal could bring the curtain down on the fractious relations between the Bakries, one of Indonesia's wealthiest and most influential families, and another of the Bumi's original backers, financier Nat Rothschild. However, on Tuesday 16th Rothschild resigned from the board of Bumi, saying he had lost confidence in the management's ability to stand up for investors.

In addition, the Bakrie Group also made a conditional proposal on Thursday 11th to buy back the remaining 18.9% shareholding in Bumi Tbk for cash before Christmas 2012, and made a conditional proposal to make a cash offer within the next six months for the company's approximately 84.7% shareholding in PT Berau Coal Energy Tbk.

In Wednesday's (17th) statement, Bumi said that it has requested its independent Non-Executive Directors to review the proposals on their own merits and report back to the board.

Julian Horn-Smith, Senior Independent Director of Bumi said: "The proposals put forward by Long Haul will receive the full attention of the independent non-executive Directors of Bumi. We have appointed Rothschild Group, acting as an unconnected and independent financial adviser, to evaluate each of these proposals, on which the board has not yet formed a view. Our objective is to ensure all shareholders are treated fairly and we will update the market as soon as practicable."

The company said it will not make any recommendations regarding the proposals until the ongoing investigation into its Indonesian operations is "appropriately advanced".

The share price rose 1.89% to 254p by 15:30.

NR

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How to invest today? Look to the past, not the future
Investment strategy

How to invest today? Look to the past, not the future

The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new norm…
18 Aug 2022
A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022